Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.

ABSTRACT:

Background

Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal renal function, the benefits of modifying lipid levels on cardiovascular outcomes in patients with ESRD on haemodialysis have yet to be confirmed in large prospective randomised trials. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA) will be the first large-scale international trial to assess the effects of statin therapy on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis.

SUBMITTER: Fellstrom B 

PROVIDER: S-EPMC1175096 | biostudies-literature | 2005 May

REPOSITORIES: biostudies-literature